German pharmaceutical company Stada is considering a €6 billion acquisition of Cooper Consumer Health from its private equity backers, according to people familiar with the matter. The move comes as Stada actively pursues new targets following record profit performance in recent periods.

The potential deal would mark a significant expansion for Stada into the consumer health segment. Private equity firm CVC has owned Cooper Consumer Health and is likely seeking an exit after building up the business. For Stada, the acquisition aligns with its strategy of growing through selective purchases when financial performance is strong.

The €6 billion valuation represents a premium for Cooper's portfolio of over-the-counter medications and health products. This transaction would continue the trend of consolidation in consumer healthcare, where larger pharma companies seek diversified revenue streams. Stada's cash-rich position following strong earnings provides the financial flexibility for such a major acquisition.